Drugs for Duchenne Muscular Dystrophy (DMD) Market, Global Outlook and Forecast 2023-2028

Report ID: 1212099 | Published Date: Jan 2025 | No. of Page: 62 | Base Year: 2024 | Rating: 4.1 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction to Research & Analysis Reports
    1.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Overall Market Size
    2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size: 2021 VS 2028
    2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Drugs for Duchenne Muscular Dystrophy (DMD) Players in Global Market
    3.2 Top Global Drugs for Duchenne Muscular Dystrophy (DMD) Companies Ranked by Revenue
    3.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Companies
    3.4 Top 3 and Top 5 Drugs for Duchenne Muscular Dystrophy (DMD) Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Drugs for Duchenne Muscular Dystrophy (DMD) Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Drugs for Duchenne Muscular Dystrophy (DMD) Players in Global Market
        3.6.1 List of Global Tier 1 Drugs for Duchenne Muscular Dystrophy (DMD) Companies
        3.6.2 List of Global Tier 2 and Tier 3 Drugs for Duchenne Muscular Dystrophy (DMD) Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Markets, 2021 & 2028
        4.1.2 Eteplirsen
        4.1.3 Deflazacort
        4.1.4 Ataluren
    4.2 By Type - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue & Forecasts
        4.2.1 By Type - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, 2017-2022
        4.2.2 By Type - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, 2023-2028
        4.2.3 By Type - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2021 & 2028
        5.1.2 Hospitals
        5.1.3 Clinics
        5.1.4 Home Care
    5.2 By Application - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue & Forecasts
        5.2.1 By Application - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, 2017-2022
        5.2.2 By Application - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, 2023-2028
        5.2.3 By Application - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2021 & 2028
    6.2 By Region - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue & Forecasts
        6.2.1 By Region - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, 2017-2022
        6.2.2 By Region - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, 2023-2028
        6.2.3 By Region - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, 2017-2028
        6.3.2 US Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.3.3 Canada Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.3.4 Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, 2017-2028
        6.4.2 Germany Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.4.3 France Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.4.4 U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.4.5 Italy Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.4.6 Russia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.4.7 Nordic Countries Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.4.8 Benelux Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, 2017-2028
        6.5.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.5.3 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.5.4 South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.5.5 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.5.6 India Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, 2017-2028
        6.6.2 Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.6.3 Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, 2017-2028
        6.7.2 Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.7.3 Israel Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.7.4 Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
        6.7.5 UAE Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2017-2028
7 Players Profiles
    7.1 Sarepta Therapeutics
        7.1.1 Sarepta Therapeutics Corporate Summary
        7.1.2 Sarepta Therapeutics Business Overview
        7.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Major Product Offerings
        7.1.4 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in Global Market (2017-2022)
        7.1.5 Sarepta Therapeutics Key News
    7.2 PTC Therapeutics
        7.2.1 PTC Therapeutics Corporate Summary
        7.2.2 PTC Therapeutics Business Overview
        7.2.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Major Product Offerings
        7.2.4 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in Global Market (2017-2022)
        7.2.5 PTC Therapeutics Key News
    7.3 Pfizer
        7.3.1 Pfizer Corporate Summary
        7.3.2 Pfizer Business Overview
        7.3.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Major Product Offerings
        7.3.4 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in Global Market (2017-2022)
        7.3.5 Pfizer Key News
    7.4 Bristol-Myers Squibb
        7.4.1 Bristol-Myers Squibb Corporate Summary
        7.4.2 Bristol-Myers Squibb Business Overview
        7.4.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Major Product Offerings
        7.4.4 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in Global Market (2017-2022)
        7.4.5 Bristol-Myers Squibb Key News
    7.5 Italfarmaco
        7.5.1 Italfarmaco Corporate Summary
        7.5.2 Italfarmaco Business Overview
        7.5.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Major Product Offerings
        7.5.4 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in Global Market (2017-2022)
        7.5.5 Italfarmaco Key News
    7.6 Santhera Pharmaceuticals
        7.6.1 Santhera Pharmaceuticals Corporate Summary
        7.6.2 Santhera Pharmaceuticals Business Overview
        7.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Major Product Offerings
        7.6.4 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in Global Market (2017-2022)
        7.6.5 Santhera Pharmaceuticals Key News
    7.7 WaVe life Science
        7.7.1 WaVe life Science Corporate Summary
        7.7.2 WaVe life Science Business Overview
        7.7.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Major Product Offerings
        7.7.4 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in Global Market (2017-2022)
        7.7.5 WaVe life Science Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

List of Tables
    Table 1. Drugs for Duchenne Muscular Dystrophy (DMD) Market Opportunities & Trends in Global Market
    Table 2. Drugs for Duchenne Muscular Dystrophy (DMD) Market Drivers in Global Market
    Table 3. Drugs for Duchenne Muscular Dystrophy (DMD) Market Restraints in Global Market
    Table 4. Key Players of Drugs for Duchenne Muscular Dystrophy (DMD) in Global Market
    Table 5. Top Drugs for Duchenne Muscular Dystrophy (DMD) Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Drugs for Duchenne Muscular Dystrophy (DMD) Product Type
    Table 9. List of Global Tier 1 Drugs for Duchenne Muscular Dystrophy (DMD) Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Drugs for Duchenne Muscular Dystrophy (DMD) Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2023-2028
    Table 30. Sarepta Therapeutics Corporate Summary
    Table 31. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Offerings
    Table 32. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$, Mn), (2017-2022)
    Table 33. PTC Therapeutics Corporate Summary
    Table 34. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Offerings
    Table 35. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$, Mn), (2017-2022)
    Table 36. Pfizer Corporate Summary
    Table 37. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Offerings
    Table 38. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$, Mn), (2017-2022)
    Table 39. Bristol-Myers Squibb Corporate Summary
    Table 40. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Offerings
    Table 41. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$, Mn), (2017-2022)
    Table 42. Italfarmaco Corporate Summary
    Table 43. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Offerings
    Table 44. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$, Mn), (2017-2022)
    Table 45. Santhera Pharmaceuticals Corporate Summary
    Table 46. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Offerings
    Table 47. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$, Mn), (2017-2022)
    Table 48. WaVe life Science Corporate Summary
    Table 49. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Offerings
    Table 50. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type in 2021
    Figure 2. Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application in 2021
    Figure 3. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in 2021
    Figure 8. By Type - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share, 2017-2028
    Figure 12. US Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share, 2017-2028
    Figure 16. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 17. France Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share, 2017-2028
    Figure 24. China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 28. India Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share, 2017-2028
    Figure 30. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share, 2017-2028
    Figure 33. Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (US$, Mn), 2017-2028
    Figure 37. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
62
Frequently Asked Questions
Drugs for Duchenne Muscular Dystrophy Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Drugs for Duchenne Muscular Dystrophy Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Drugs for Duchenne Muscular Dystrophy Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports